Xenon Pharmaceuticals Inc.
XENE
$42.88
-$0.63-1.45%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 7.50M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 7.50M | -- | -- |
| Cost of Revenue | 77.05M | 74.99M | 61.20M | 59.47M | 56.97M |
| Gross Profit | -77.05M | -74.99M | -53.70M | -59.47M | -56.97M |
| SG&A Expenses | 19.28M | 19.24M | 19.04M | 18.01M | 16.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 96.34M | 94.23M | 80.24M | 77.48M | 73.68M |
| Operating Income | -96.34M | -94.23M | -72.74M | -77.48M | -73.68M |
| Income Before Tax | -90.22M | -85.33M | -64.62M | -69.53M | -63.11M |
| Income Tax Expenses | 677.00K | -626.00K | 427.00K | -3.85M | -320.00K |
| Earnings from Continuing Operations | -90.90M | -84.71M | -65.05M | -65.69M | -62.79M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -90.90M | -84.71M | -65.05M | -65.69M | -62.79M |
| EBIT | -96.34M | -94.23M | -72.74M | -77.48M | -73.68M |
| EBITDA | -95.70M | -93.60M | -72.08M | -76.84M | -73.01M |
| EPS Basic | -1.15 | -1.07 | -0.83 | -0.84 | -0.81 |
| Normalized Basic EPS | -0.71 | -0.68 | -0.51 | -0.55 | -0.51 |
| EPS Diluted | -1.15 | -1.07 | -0.83 | -0.84 | -0.81 |
| Normalized Diluted EPS | -0.71 | -0.68 | -0.51 | -0.55 | -0.51 |
| Average Basic Shares Outstanding | 79.25M | 78.95M | 78.69M | 78.39M | 77.93M |
| Average Diluted Shares Outstanding | 79.25M | 78.95M | 78.69M | 78.39M | 77.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |